Result of AGM

RNS Number : 7644A

Tissue Regenix Group PLC

03 June 2021

 

Tissue Regenix Group plc

("Tissue Regenix" or "the Group")

Result of AGM

Tissue Regenix (AIM: TRX), the regenerative medical devices company, announces that at the AGM held earlier today, all resolutions were duly passed.

The results of the poll are set out below:

Resolution		In favour	%	Against	%	Withheld
1	Ordinary	3,399,235,541	100	0	0	546,855
2	Ordinary	3,399,212,980	99.99	76,421	0.01	569,416
3	Ordinary	3,399,212,980	99.99	76,421	0.01	569,416
4	Ordinary	3,399,656,835	99.99	16,274	0.01	125,561
5	Ordinary	3,399,656,835	99.99	74,846	0.01	125,561
6	Ordinary	3,399,656,835	99.99	16,274	0.01	125,561
7	Ordinary	3,399,656,835	99.99	17,849	0.01	125,561
8	Ordinary	3,399,338,541	99.99	194,449	0.01	443,855
9	Ordinary	3,399,338,541	99.99	17,849	0.01	443,855
10	Ordinary	3,397,632,396	99.90	3,420,838	0.10	2,150,000
11	Special	3,397,632,396	99.31	23,283,587	0.69	2,150,000
12	Special	3,399,782,396	99.88	4,162,711	0.12	0

NB: Percentage of Votes cast excludes Withheld votes

The full text of the resolutions passed at the AGM may be found in the Notice of AGM published on 28 April 2021.

For more information:

Tissue Regenix Group plc David Cocke, Chief Financial Officer	www.tissueregenix.com Via Walbrook PR
Stifel Nicolaus Europe Limited (Nominated Adviser and Broker) Ben Maddison / Alex Price	Tel:  [phone]
Walbrook PR Ltd Alice Woodings / Paul McManus	Tel: [phone]          [e-mail]

About Tissue Regenix ( www.tissueregenix.com )

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn-out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and soft tissue scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopaedic, foot & ankle, dental, and sports medicine surgical procedures.

The information contained in this notification is disclosed in accordance with the requirements of the EU Market Abuse Regulation as it forms part of UK law by virtue of the European Union (Withdrawal) Act 2018. The notification form is set out below.

 

END

 

 

RAGSSDFEDEFSEDM